Stroke therapy: Is spironolactone the Holy Grail?

Endocrinology

Volumn 149, Issue 8, 2008, Pages 3761-3763

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DISUFENTON SODIUM; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ANGIOGENESIS; APOPTOSIS; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HUMAN; HYPERALDOSTERONISM; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT FAILURE;

ALDOSTERONE ANTAGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STROKE;

EID: 47949124405     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0724     Document Type: Short Survey

References (26)

1. Hankey GJ 2006 Potential new risk factors for ischemic stroke: what is their potential? Stroke 37:2181-2188
2. Smith WS 2004 Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol 15:S3-12
3. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL 2003 Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 34:1106-1113
4. Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G 2004 Cerebrovascular risk factors and clinical classification of strokes. Semin Vasc Med 4:287-303
5. Savitz SI, Fisher M 2007 Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 61:396-402
6. Savitz SI, Schabitz WR 2008 A Critique of SAINT II: wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke. Stroke 39:1389-1391
7. Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger M, Schwab ME, Vivien D, Wieloch T, Dirnagl U 2008 Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis 25:268-278
8. Oyamada N, Sone M, Miyashita K, Park K, Taura D, Inuzuka M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N, Itoh H, Nakao K 2008 The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149:3764-3777
9. Conn JW, Knopf RF, Nesbit RM 1964 Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107:159-172
10. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T 1995 Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18:370-373
11. Rocha R, Stier Jr CT 2001 Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12:308-314
12. Dorrance AM, Osborn HL, Grekin R, Webb RC 2001 Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281:R944-950
13. Rigsby CS, Pollock DM, Dorrance AM 2007 Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 73:198-205
14. Schiffrin EL 2006 Effects of aldosterone on the vasculature. Hypertension 47:312-318
15. Spengos K, Tsivgoulis G, Zakopoulos N 2006 Blood pressure management in acute stroke: a long-standing debate. Eur Neurol 55:123-135
16. Fischer AK, von Rosenstiel P, Fuchs E, Goula D, Almeida OF, Czeh B 2002 The prototypic mineralocorticoid receptor agonist aldosterone influences neurogenesis in the dentate gyrus of the adrenalectomized rat. Brain Res 947:290-293
17. Sloviter RS, Valiquette G, Abrams GM, Ronk EC, Sollas AL, Paul LA, Neubort S 1989 Selective loss of hippocampal granule cells in the mature rat brain after adrenalectomy. Science 243:535-538
18. Wong EY, Herbert J 2004 The corticoid environment: a determining factor for neural progenitors' survival in the adult hippocampus. Eur J Neurosci 20:2491-2498
19. McCullers DL, Herman JP 1998 Mineralocorticoid receptors regulate bcl-2 and p53 mRNA expression in hippocampus. Neuroreport 9:3085-3089
20. Almeida OF, Conde GL, Crochemore C, Demeneix BA, Fischer D, Hassan AH, Meyer M, Holsboer F, Michaelidis TM 2000 Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J 14:779-790
21. Macleod MR, Johansson IM, Soderstrom I, Lai M, Gido G, Wieloch T, Seckl JR, Olsson T 2003 Mineralocorticoid receptor expression and increased survival following neuronal injury. Eur J Neurosci 17:1549-1555
22. Cheng J, Alkayed NJ, Hurn PD 2007 Deleterious effects of dihydrotestosterone on cerebral ischemic injury. J Cereb Blood Flow Metab 27:1553-1562
23. Gibson CL, Gray LJ, Bath PM, Murphy SP 2008 Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131:318-328
24. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472
25. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121-125
26. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717